Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBlue Cross Blue Shield RI Genetic Testing Coverage…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Genetic Testing Services

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing medical necessity, coverage, and prior authorization requirements for genetic and molecular testing services for BCBSRI members (Medicare Advantage and Commercial products). Applies to ordering providers and laboratories interacting with BCBSRI.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyGenetic Testing Services
    Policy CodePolicy N/A
    Change TypeRoutine update — no material clinical or coverage changes
    Effective Date06/01/2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests via the BCBSRI online prior authorization tool (or fax for non-participating providers) and consult the linked Genetic Testing Codes and Coverage spreadsheet to determine authorization requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    06/01/2026

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy effective date
    Medicare AdvantagePlans requiring prior auth
    Recommended for CommercialCommercial prior auth status
    External spreadsheetCoding grid
    Limitations notedExplicit limitations listed
    ExtensiveReferences cited

    Coverage and Medical Necessity Criteria

    Medical Necessity Criteria

    Covered when ALL of the following are met (per category or specific online criteria):

    Carrier screening (preconception or prenatal): One or both individuals have a first- or second-degree relative who is affected; one individual is a known carrier; one or both individuals are from a population with a carrier rate that exceeds a threshold appropriate for testing for that condition; AND previous carrier screening or targeted testing for the gene variant(s) of interest has not been performed.

    First- and second-degree relatives defined in policy (first-degree: biological parent, brother, sister, or child; second-degree: grandparent, aunt/uncle, niece/nephew, grandchild, half‑sibling).

    General genetic testing indications: To confirm a suspected diagnosis in a patient with signs and/or symptoms; to identify a causative etiology for a clinical syndrome with multiple possible underlying conditions; or testing an asymptomatic individual to determine future risk of disease.

    Applied via online authorization tool/InterQual where specific criteria sets exist.

    Genetic testing for cancer: Testing an asymptomatic patient to determine future risk of cancer; or therapeutic testing of cancer cells (somatic) from an affected individual to direct targeted treatment based on specific somatic variants.

    Context-specific criteria applied via the online authorization tool.

    Not Medically Necessary when Evidence Insufficient

    General limitations and coverage stance

    Tests considered not medically necessary when evidence is insufficient: Genetic tests that lack demonstrated clinical utility or sufficient evidence of clinical validity are considered not medically necessary because the evidence is insufficient to determine effects on health outcomes.

    Policy identifies multiple tests with extremely limited published data or insufficient evidence demonstrating clinical validity as not medically necessary.

    Tests considered not medically necessary or not covered include those with insufficient clinical evidence or limited published data demonstrating clinical validity or utility. When evidence does not support that a test will meaningfully inform patient management or improve health outcomes, the service may be denied as not medically necessary or not covered. Whole panels may be considered not covered when component genes or variants within the panel lack demonstrated clinical usefulness.

    Genetic tests that lack demonstrated clinical utility or do not have sufficient evidence of clinical validity are excluded from coverage as not medically necessary. The policy specifically identifies tests where published data are extremely limited or where validity has not been established as examples that will be excluded from medical necessity coverage.

    For both Medicare Advantage and Commercial products, when prior authorization is indicated coverage is contingent on meeting the online authorization criteria and policy requirements. Genetic testing services are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial Products when there is insufficient clinical evidence, results would not reasonably be used in patient management, or the service is unlikely to affect therapeutic decision-making.

    The policy notes that there are several specific tests with extremely limited published data and insufficient evidence of clinical validity; such tests are considered to have inadequate evidence to determine impact on health outcomes and are therefore not medically necessary.

    Covered Indications for Genetic Testing

    Carrier Screening — Covered Indications

    Eligibility for carrier screening: One or both individuals being screened must have a first- or second-degree relative affected, OR one individual is a known carrier, OR one or both individuals are from a population with a high carrier rate for the condition; AND prior targeted testing for the variant(s) of interest has not been performed.

    First- and second-degree relative definitions provided in policy.

    Documentation and prior testing: No prior targeted carrier testing for the specific variant(s) of interest has been performed for the individual(s) seeking screening.

    Referenced as requirement for carrier screening in the online authorization criteria.

    Population-based testing threshold: Individuals from populations known to have a carrier rate that exceeds an appropriate threshold for testing for the particular condition meet criteria for screening.

    Population carrier-rate thresholds are applied as appropriate for specific conditions per authorization criteria.

    Eligibility and Patient Selection

    Coverage for carrier screening requires documented family- or population-based risk: one or both individuals must have a first- or second-degree relative who is affected, or one individual is a known carrier, or one or both individuals are from a population with an elevated carrier rate; additionally, previous carrier screening or targeted testing for the variant(s) of interest must not have been performed prior to coverage.

    Additional eligibility requirements and decision nodes are applied in the online authorization tool and depend on the category of testing; refer to the BCBSRI authorization criteria for condition- and test-specific eligibility details.

    Other eligibility considerations (for example, prior testing performed, symptomatic status, or diagnostic intent) are evaluated through the authorization workflow and associated criteria; providers should use the online prior authorization tool and the linked code/coverage grid for precise guidance.

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Medicare Advantage plans and recommended for Commercial Products. Submit authorization requests via the BCBSRI online prior authorization tool (available to BCBSRI-participating providers). Providers who are not BCBSRI-participating may fax requests to Utilization Management at (401) 272-8885. If a genetic test is not found in the online authorization tool, fax the request to Utilization Management at (401) 272-8885. Panel testing: prior authorization is required for each component and/or gene/gene variant of panel testing when the panel is represented by multiple CPT codes; each individual CPT code must be entered into and processed through the online authorization tool independently. Effective 10/1/2025, for Fully-Funded Commercial Products only, prior authorization requests may not be needed when the requesting physician is a BCBSRI contracted Primary Care Provider (Internal Medicine, Pediatric Medicine, Family Practice, Obstetrics and Gynecology, Doctor of Osteopathic Medicine, NP/PCP, PA).

    • Submit authorizations via BCBSRI online prior authorization tool
    • Fax for non-participating providers or tests not in the tool: (401) 272-8885
    • Panel testing: enter each CPT component separately
    • PCP exemption for Fully-Funded Commercial Products effective 10/1/2025

    Genetic Testing Codes and Coverage

    Genetic Testing Codes and Coverage (referenced external grid)mixed
    See attached gridGenetic Testing Codes and Coverage Effective 6/1/2026 spreadsheet (external link)
    Genetic Testing Codes and Coveragemixed
    see spreadsheetGenetic testing CPT/HCPCS codes and coverage determinations are listed in the linked Genetic Testing Codes and Coverage spreadsheet effective 6/1/2026.
    Billing Rule

    Refer to external code/authorization grid for code‑level rules

    Refer to the external Genetic Testing Codes and Coverage spreadsheet for code‑level authorization, coverage, and documentation rules — this policy defers code‑specific determinations to the linked grid.

    • The attached spreadsheet provides code‑level indications of coverage and authorization requirements effective 6/1/2026.
    • Use the grid for the most up‑to‑date code‑specific rules.
    Note

    Check the Genetic Testing Codes & Coverage spreadsheet to confirm authorization and documentation needs by code

    Providers must consult the BCBSRI Genetic Testing Codes and Coverage spreadsheet (linked in the policy) to determine which CPT codes and clinical indications require prior authorization and what documentation is required to meet medical necessity.

    Tests Not Covered / Not Medically Necessary

    Genetic panels or individual tests that lack sufficient clinical evidence or clinical utility are listed as not covered. Panels whose component genes or variants do not have demonstrated usefulness for guiding management may be denied in their entirety for Medicare Advantage and deemed not medically necessary for Commercial Products.

    Tests determined to lack clinical validity or utility based on insufficient evidence are explicitly categorized as not medically necessary. When available data are inadequate to establish that a test will affect patient outcomes or clinical decision-making, coverage will be denied.

    Definitions and Test Types

    Genomic Sequencing Procedures / Molecular Pathology
    DefinitionGenomic Sequencing Procedures (GSPs) and other molecular multianalyte assays are DNA and/or RNA sequence analysis methods that simultaneously assay multiple genes or genetic regions relevant to a clinical situation; technology typically used is massively parallel sequencing (eg, next‑generation sequencing [NGS]) and may target specific gene combinations, the exome, or the genome.
    Sample typesGSPs are performed on nucleic acids from germline (constitutional) or neoplastic (tumor) samples.
    Scope of panelsA genetic panel evaluates multiple genes simultaneously (eg, NGS, massive parallel sequencing, chromosomal microarray) rather than sequential single‑gene testing; panel composition is variable and lab‑dependent.
    Code selectionCode selection is typically based on the specific gene(s) being analyzed and genes are described using HUGO‑approved gene names.
    PurposeUsed to detect variants indicative of germline disorders, somatic neoplasia, or to test for histocompatibility antigens (eg, HLA).

    Background and Rationale

    Genetic tests can guide interventions in symptomatic or asymptomatic individuals by identifying causal variants, estimating future risk, informing prognosis, and directing treatment selection. Molecular pathology and genomic sequencing procedures (eg, NGS) analyze DNA/RNA to detect germline or somatic variants, and multianalyte assays/MAAAs may generate algorithmic scores; the clinical utility of these technologies is condition- and test-specific and subject to the limitations of testing methods (for example, potential to miss variants, identification of variants of uncertain significance, genetic heterogeneity, and laboratory error).

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyGenetic Testing Services
    Policy CodePolicy N/A
    Change TypeRoutine update — no material clinical or coverage changes
    Effective Date06/01/2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests via the BCBSRI online prior authorization tool (or fax for non-participating providers) and consult the linked Genetic Testing Codes and Coverage spreadsheet to determine authorization requirements.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCovered Indications for Genetic TestingEligibility and Patient SelectionProvider Actions, Prior Authorization, and DocumentationGenetic Testing Codes and CoverageTests Not Covered / Not Medically NecessaryDefinitions and Test TypesBackground and Rationale

    Diagnostic Testing — Covered Indications

    Diagnostic testing in symptomatic individuals: Genetic testing is covered to confirm a suspected diagnosis in a patient with signs and/or symptoms of the condition.

    Use InterQual/online authorization criteria for condition-specific application.

    Etiologic diagnosis for syndromic presentations: Covered to identify a causative etiology for a clinical syndrome when multiple possible underlying genetic conditions exist.

    Applied where testing will benefit the individual by informing diagnosis or management.

    Cancer-Related Genetic Testing — Covered Indications

    Germline cancer risk assessment: Germline (inherited) testing is covered for asymptomatic patients when used to determine future cancer risk.

    Applied per online criteria for cancer-related testing.

    Somatic tumor testing to inform therapy: Somatic testing of tumor tissue is covered when used to direct targeted treatment for an affected individual based on identified somatic variants.

    Therapeutic, somatic testing is intended to benefit the individual by guiding targeted treatment decisions.

    Documentation Required

    Submission and Documentation Requirements

    Submit required clinical documentation with authorization requests to demonstrate medical necessity as specified in the online authorization tool criteria. Provide supporting clinical information that links the requested test to the patient’s signs, symptoms, family history, diagnosis codes, and prior testing where applicable. Only the ordering physician may participate in the authorization, appeal, or other administrative processes related to prior authorization/medical necessity; laboratories or third parties are not permitted to obtain authorization on behalf of the ordering physician.

    • Include clinical rationale, relevant diagnosis codes, prior test results, and family history as applicable
    • Only the ordering physician may submit or pursue authorizations/appeals — labs/third parties may not act on the provider’s behalf
    Billing Rule

    Check Coding/Authorization Grid

    Coverage, medical necessity, and whether prior authorization is required vary by code, indication, and product. Providers should consult the BCBSRI Genetic Testing Codes and Coverage spreadsheet to determine which CPT/PLA codes and indications require authorization or are covered, medically necessary, not medically necessary, or not covered.

    • See: Genetic Testing Codes and Coverage Effective 6/1/2026 spreadsheet
    • Use the spreadsheet to identify codes/indications requiring prior authorization and appropriate diagnosis coding
    Denial Risk

    Tests with Insufficient Evidence — Denial Risk

    There are several tests and genetic panels with insufficient published evidence of clinical validity or clinical utility. Tests lacking sufficient evidence are considered not medically necessary and are at high risk for denial. Prior authorization and supporting documentation should demonstrate clinical validity and expected impact on patient management to reduce denial risk.

    • Tests/panels with insufficient evidence may be denied as not medically necessary
    • Document how results will influence clinical management to support medical necessity
    Note

    Consult the BCBSRI Genetic Testing Codes and Coverage Spreadsheet

    Providers should consult the BCBSRI Genetic Testing Codes and Coverage spreadsheet to determine specific codes and indications that require authorization and to review coverage status or related policy references. The code grid provides guidance for diagnosis coding, PLA/MAAA rules, and per-code coverage determinations.

    • Reference the downloadable code grid for per-code coverage and comments
    • Follow related policy links referenced in the grid for tests governed by other BCBSRI policies
    Step Therapy

    Step Therapy / Sequencing Guidance

    No specific step therapy sequencing guidance is provided within this policy section. For sequencing, prior authorization requirements, and coverage order of tests, consult the BCBSRI Genetic Testing Codes and Coverage spreadsheet and related policies referenced therein.

    • Follow the external coding/coverage grid for sequencing or step requirements
    Note

    Ordering Physician Responsibility

    Ordering physician must be the individual to submit and pursue authorizations and appeals. Rules differ for Fully-Funded Commercial Products where select BCBSRI-credentialed primary care specialties may be exempt from prior authorization requirements per the PCP exemption effective 10/1/2025.

    • Only the ordering physician may be involved in authorization/appeal processes
    • PCP exemption applies to listed specialties for Fully-Funded Commercial Products beginning 10/1/2025
    • The spreadsheet identifies codes that may be covered, medically necessary if criteria met, not medically necessary, or not covered.
    • For panel tests filed with specific individual CPT codes, refer to the grid and related policies (eg, PLA and MAAA) for coverage guidance.
    MAAA (Multianalyte Assays with Algorithmic Analyses)
    DefinitionMultianalyte Assays with Algorithmic Analyses (MAAAs) utilize multiple results from panels of assays (molecular pathology, FISH, non‑nucleic acid assays) and apply an algorithm — often producing a numeric score or probability typically unique to a single laboratory or manufacturer.
    ComponentsMay include molecular assays, fluorescent in situ hybridization, protein or other analyte measurements and may incorporate other patient information into the algorithmic output.
    ReportingResults are typically reported as a score(s) or a probability derived from algorithmic analysis rather than as individual variant calls alone.
    Relation to panelsGenetic panels evaluated by NGS or microarray assess multiple genes simultaneously; MAAAs are conceptually distinct when an algorithm integrates multiple assay results to produce a composite result.
    Germline versus Somatic Variants
    Germline variantPresent in the DNA of every cell from conception, including gonadal cells; germline variants may be inherited and can be transmitted to offspring.
    Somatic variantArise over time in specific cells or cell lineages and are restricted to those cells; if not present in gonadal cells, somatic variants are not passed to offspring.
    Clinical implicationGermline testing addresses inherited risk and carrier status; somatic testing (eg, tumor) is used to characterize neoplasia and to guide targeted therapies.
    Variant of Uncertain Significance (VUS)
    DefinitionVariant of Uncertain Significance (VUS): a genetic variant identified by testing whose association with disease risk or clinical outcome is not clearly established.
    Prevalence with NGSVUS are found commonly and in greater numbers with newer sequencing techniques such as NGS compared with direct (Sanger) sequencing.
    Implication for careA VUS does not necessarily determine clinical outcome or management and may limit the clinical utility of a test until reclassification or further evidence is available.
    Testing limitationIdentification of VUS is one of several limitations of genetic testing, which also include incomplete variant detection, genetic heterogeneity, phenotypic heterogeneity, and laboratory error.